Essential hypertension is associated with an increased incidence of arterial thrombotic complications, predominantly myocardial infarction and ischemic stroke. 1,2 A direct relationship exists between the level of either systolic or diastolic blood pressure (BP) and the mortality from cardiovascular (CV) events, independent of other CV risk factors; and BP lowering with antihypertensive therapy exerts a beneficial effect in terms of reduction of CV complications, with no apparent threshold for target BP, at least down to values of 115/75 mm Hg (ref. 2).
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The prothrombotic state in hypertension is sustained by a number of factors (Figure 1) . First, endothelial damage and clinically undetected atherosclerosis, which are usually present in hypertensive patients, confer procoagulant properties to the vascular endothelium. This effect seems to be mediated by the expression of tissue factor, von Willebrand Factor (vWF), and P-selectin on the endothelial cellular surface, which together with the exposure of subendothelial collagen, are able to initiate the coagulation cascade or promote platelet activation at the lesion sites. 3, 4 Second, an imbalance between procoagulant and fibrinolytic activity in the peripheral blood of hypertensive subjects has been observed. Specifically, increased circulating levels of plasminogen activator inhibitor-1, antithrombin III, and protein C have been reported, 5 as have increased fibrinogen and vWF antigen, with the latter being an independent predictor of target-organ damage. 6 These abnormalities appear to be related to the degree and duration of hypertension: vWF antigen is not elevated in subjects with mild essential hypertension but increased in patients with severe hypertension, 5 and fibrinogen levels correlate with degree of left ventricular hypertrophy. 7 Well-controlled hypertensive patients (BP < 140/90 mm Hg) have lower levels of vWF antigen than those observed in patients with BP ≥ 140/90 mm Hg (ref. 8) , indicating that antihypertensive treatment may have a beneficial effect on at least some of these abnormalities. 9 Third, hemodynamic disturbances, either due to the presence of atherosclerotic lesions or increased blood viscosity, may contribute to the prothrombotic state. Blood viscosity has been demonstrated to be increased in hypertensive subjects, and in fact to correlate independently with BP level. [5] [6] [7] 10 Here, we review the evidence that platelet activity is increased in essential hypertension, as well as the mechanisms by which this may occur. We also consider whether antiplatelet therapy, an important and established part of treatment for hypertensives at high CV risk, may play a potentially useful role in hypertensives at lower levels of risk, and specifically whether P2Y 12 receptor antagonists such as clopidogrel may have possible advantages over aspirin in this respect. We performed a PubMed search using the terms BP, platelets, aspirin, clopidogrel, antiplatelet therapy, and essential hypertension. Platelet activation in response to a wide variety of stimuli is known to trigger a complex series of intracellular pathways leading to changes in shape and the release of intracellularly stored components. These events are dependent on an increase in concentration of calcium ions (Ca 2+ ) in the cytosol. 11 Most agonists activate the second messenger enzyme phospholipase C, which in turn catalyzes the generation of diacylglycerol and inositol 1,4,5-trisphosphate within the platelet. This latter stimulates the release of Ca 2+ from intracellular stores and promotes influx of external Ca 2+ . High Ca 2+ concentration also triggers the release of arachidonic acid from platelet membrane phospholipids and its conversion to thromboxane A 2 . Diacylglycerol acts on protein kinase C, which contributes to platelet activation mediated via extracellular signal-regulated kinases. 12, 13 Platelet activation is believed to contribute importantly to the increased risk of thrombosis in essential hypertension, and this may be mediated through a variety of mechanisms. Neurohumoral activation is believed to play an important role in this. Increased activity of the sympathetic nervous system facilitates norepinephrine release from adrenergic nerve terminals and enhances the responsiveness of adrenergic receptors. 14 Importantly, increased sympathetic tone activates platelets, contributing to the hypercoagulability observed in hypertension. 15 Additionally, upregulation of platelet α 2 -adrenoreceptors in essential hypertension leads to a greater sensitivity to the proaggregatory effect of catecholamines. 16 The renin-angiotensin system, which plays a major role in the pathogenesis of essential hypertension in some patients, also affects platelet function through its main mediator angiotensin II. 17 Furthermore, infusion of angiotensin II in humans increases circulating levels of soluble P-selectin and β-thromboglobulin, and also promotes platelet-fibrinogen binding. 18 All these effects appear to be mediated by the interaction of angiotensin II with AT 1 receptors on platelet surface, with the consequent activation of phospholipase C.
Endothelial dysfunction, which refers to alteration in the vasoactive, anti-inflammatory, and anticoagulant properties of the endothelium, is mainly detected as a loss of endothelium-derived nitric oxide (NO) bioactivity. Among other effects, diminished endothelial NO leads to enhanced platelet adhesion onto the already activated endothelial cells, 19 and increased platelet aggregation at sites of vascular injury. 20 Additionally, the role of platelet-derived NO in causing platelet activation in essential hypertension has been investigated. Platelets express NO synthase type 3, and a number of studies suggest that platelet NO synthase type 3 is dysfunctional in essential hypertension. For example, aggregating platelets of hypertensive patients exhibit a diminished response to N G -monomethyl-l-arginine (an inhibitor of NO synthase) as compared to those of normotensive controls. 21 l-Arginine transport is decreased in platelets from hypertensives due to downregulation in activity of the y + L transport system. 22 Inhibition of l-arginine transport by N G ,N Gdimethyl-l-arginine (asymmetric dimethylarginine) is more pronounced in platelets from hypertensive patients, 23 and increased circulating levels of asymmetric dimethylarginine have been found in hypertensive subjects. 24 Recently, impaired activation of platelet NO synthase type 3 in response to albuterol and collagen has been reported in untreated hypertensive patients. 25 Platelet-derived NO has been reported to suppress platelet aggregation, decrease platelet adhesion to the endothelium, and inhibit the formation of monocyte-platelet aggregates (MPAs). 26 All of these effects may be abrogated in the presence of a dysfunctional NO synthase type 3, in platelets of patients with essential hypertension Although the above studies suggest that platelet NO biosynthesis is dysfunctional in essential hypertension, there are some studies which suggest that intraplatelet levels of cGMP (the second messenger for NO) are not different in resting platelets of hypertensive patients and normotensive controls. 27, 28 The precise role of dysfunction of the platelet NO/cGMP system in uncomplicated human hypertension therefore remains the subject of controversy.
Shear effects may also be important in causing platelet activation in the circulation of patients with essential hypertension. Raised BP is associated with increased shear forces, especially adjacent to the endothelium, and this may lead to platelet degranulation and consequent platelet activation. 29 A number of indexes suggest that platelets are activated in essential hypertension ( Table 1) . Many early and mostly small studies, 17, 30, 31 but not all, 21 have shown increased platelet aggregation in hypertension. Changes in platelet volume and mass, indicative of platelet activation, have also been reported, 32 as have morphological changes suggestive of activation. 30 Additionally, markers of platelet activation, such as urinary 11-dehydrothromboxane B 2 (a spontaneous degradation product of thromboxane A 2 ) or plasma β-thromboglobulin, have been found to be elevated in hypertensive populations. 32 Basal [Ca 2+ ] i is higher in platelets from patients with essential hypertension, and the sensitivity of these platelets to an exogenous NO donor such as nitroprusside is reduced compared to those of healthy controls. 33 Expression of platelet P-selectin and circulating soluble P-selectin is increased in hypertensive patients. 34 Moreover, platelet microparticle formation is enhanced, 35 and these microparticles have been reported not only to have thrombogenic properties but also to be proinflammatory and proatherogenic. 36 MPA are formed through the binding of P-selectin on platelets to monocytic P-selectin glycoprotein ligand-1 (PSGL-1), which has been identified and cloned in leukocytes. 37 It is constitutively expressed on leukocytes and, via binding to P-selectin, mediates their rolling on endothelium and adhesion to platelets. Upon activation, platelets express P-selectin on their membrane surface. 38 As it is not expressed on resting platelets, P-selectin is considered a marker of in vivo platelet activation. It also acts as a receptor for monocytes and neutrophils and mediates their adhesion to platelets. 39 MPA levels constitute a robust, early and sensitive marker of platelet activation. Michelson et al. showed that circulating MPA level is a more sensitive marker of in vivo platelet activation than P-selectin expression on the platelet surface. 40 More recently, increased levels of MPA have been found in patients with stable coronary artery disease, 41 and in acute myocardial infarction. 42, 43 Similar findings have been reported in patients with acute coronary syndrome, 44 end-stage renal failure, 45 type 1 and type 2 diabetes mellitus, 46 ,47 cigarette smokers, 48 hypertensives, 25 and pregnant normotensive as well as preeclamptic women. 49 Apart from being a marker of platelet activation, it is believed that the interaction between platelets and monocytes represents a potential pathophysiological mechanism, which initiates and promotes atherosclerosis and thrombosis. For example, platelets are rich in unesterified cholesterol, 50, 51 which is released upon activation 52 and is donated to monocytes for cholesteryl ester formation. 53 In this way, platelets potentially contribute to the formation of foam cells in atherogenesis. Furthermore, platelets express tissue factor, 54 and upon activation they release microvesicles that transfer tissue factor to monocytes, an event highly dependent on platelet P-selectin. 55 Recently, it has been shown that mice deficient in both apolipoprotein E and P-selectin have less advanced atherosclerosis compared with those deficient in apolipoprotein E alone. 56 In addition, P-selectin induces the expression of tissue factor on monocytes, thus initiating the blood coagulation cascade. 57 It also mediates fibrin deposition in the growing thrombus, 58 and induces superoxide anion production by neutrophils and monocytes. 59, 60 It also regulates production of platelet activating factor and phagocytosis by monocytes. 61 Furthermore, exposure of monocytes to P-selectin induces the expression of tumor necrosis factor-α, monocyte chemoattractant protein-1 (ref. 62) , and cytokines such as interleukin-8. 63 Expression of CD40 ligand on the platelet surface following activation induces endothelial cells to produce chemokines and express adhesion molecules, thereby initiating an inflammatory response from leukocytes at sites of injury. 64 It has been recently shown that MPA promote formation of atherosclerotic lesions in mice deficient in apolipoprotein E, 65 and support monocyte adhesion to endothelium and cluster formation. 66 
effecT of anTihyperTensive TreaTmenT on plaTeleT acTivaTion
There are several studies that have investigated the effect of antihypertensive treatment on platelet activation. However, results have varied depending on drug class and also on platelet function test studied; this has been reviewed elsewhere in detail. 67 In general, calcium channel blockers in most studies have been found to reduce platelet aggregability. [68] [69] [70] [71] By contrast, results from studies using angiotensin-converting enzyme inhibitors or AT 1 receptor blockers are more conflicting. In some studies, no measurable effect has been seen, [72] [73] [74] whereas in others a reduction in platelet aggregation has been reported. [75] [76] [77] [78] With respect to other markers of platelet activation, inhibitors of the RAS appear to have either neutral or, in most cases, favorable effects. 79 The same applies for studies in which adrenergic blockers have been used. [80] [81] [82] Differences in the hypertensive populations of these studies, the methods for estimating platelet function, and the doses of antihypertensive agents employed may contribute substantially to the divergence in results. Thus, at present, there is no consensus as to whether any one antihypertensive drug class has more beneficial action on platelet function than another.
role of anTiplaTeleT TreaTmenT in essenTial hyperTension
A number of antiplatelet drugs have been produced and are commercially available. The most widely used is aspirin, and more recently clopidogrel (and, of late, newer P2Y 12 receptor antagonists such as prasugrel). These agents recognize distinct molecular targets involved in platelet activation, and the different properties exhibited by aspirin and clopidogrel may have an important bearing on the long-term effects of each of these agents in hypertensive subjects. Figure 2 shows the distinct pathways on which these two drugs act. Briefly, aspirin inhibits cyclooxygenase-1, which generates cyclic endoperoxides, the precursors of thromboxane A 2 synthesis, from arachidonic acid. Thromboxane A 2 is a potent proaggregatory agent, 83 essential for promoting and sustaining the aggregatory response. Clopidogrel on the other hand is a prodrug whose active metabolite inhibits platelet P2Y 12 receptors, which are an important target of ADP action on the platelet surface. P2Y 12 receptors are coupled to G i protein, and play an essential role in the full platelet response upon activation. They are responsible for ADP-induced inhibition of platelet membrane-bound adenylyl cyclase, 84 thereby inhibiting platelet production of cAMP (which inhibits platelet aggregation).
An early study showed that aspirin does not affect P-selectin expression in ADP-activated platelets, suggesting that it may not be able to regulate platelet-leukocyte interactions. 85 Subsequently, other studies in healthy subjects have confirmed that aspirin neither has effect on platelet P-selectin expression nor on platelet-leukocyte aggregation, after stimulation with ADP, thrombin and platelet-activating factor. 86 Furthermore, in clinical studies comparing the effect of different antiplatelet treatments on platelet-leukocyte interactions, P2Y 12 receptor antagonists (unlike aspirin) demonstrated effective prevention of P-selectin expression, as well as of platelet-monocyte and platelet-neutrophil aggregation, both in healthy subjects and in patients with atherosclerosis and acute coronary syndromes, as well as in those undergoing intracoronary stent implantation. 87, 88 Taking into consideration the potential proatherogenic effect of circulating MPA and activated platelets, these observations imply that treatment with clopidogrel might exert an additional protective effect, over and above aspirin, against the progression of atherosclerosis and its thrombotic complications. However, whether this is truly the case is currently far from clear, due to lack of clinical outcome data. Table 2 displays the results of a number of meta-analyses and randomized trials in which mortality from CV disease as well the incidence of CV events were studied as a function of long-term aspirin therapy, in the context of primary prevention. One of the first meta-analyses published by the AntiPlatelet Trialists Collaboration examined the effect of aspirin on vascular events in various categories of patients. In "highrisk" subjects, as defined by the presence of vascular disease or other conditions predisposing to high risk of occlusive vascular disease, aspirin (75-325 mg daily) significantly reduced the risk of serious vascular events compared to placebo. In the "low-risk" group, referring to subjects with no previous history of CV disease, the benefit of treatment with aspirin on nonfatal myocardial infarction was accompanied by a nonsignificant increase in stroke, resulting in a smaller absolute reduction in vascular events when compared to that observed in high risk subjects. 89 Because long-term therapy with aspirin almost doubles the risk of serious bleeding complications, the benefit of using aspirin in high-risk patients should outweigh the danger of serious bleeding events. 90 A more recent meta-analysis of 287 studies, which was published by the same group, has again investigated the effect of antiplatelet treatment, mainly aspirin (75-150 mg daily), but also clopidogrel and dipyridamole, on major vascular outcomes. In high-risk patients, antiplatelet treatment reduced the combined endpoint of serious vascular events by about 25% (ref. 91 ).
In the CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) study, in which >50% of subjects had hypertension, and all subjects had clinical atherosclerotic vascular disease, clopidogrel (75 mg once daily) was found to be slightly superior to aspirin (325 mg once daily) in reducing the combined risk of ischemic stroke, myocardial infarction, and vascular death, 92 although in terms of safety there were no major differences between the aspirin and clopidogrel regimens. Clopidogrel may therefore have advantages over aspirin in high-risk patients; however, a more recent study has shown that the combination of the two agents (75 mg clopidogrel and 75 mg aspirin daily) in high-risk patients was not associated with a significant reduction in major vascular events over and above that seen with clopidogrel alone, although the risk of life-threatening or major bleeding was increased in the group receiving the combination. 93 Therefore, although treatment with clopidogrel for secondary prevention in high-risk patients may be cost effective under certain conditions, 94 it remains uncertain as to whether it can be justified for use in primary prevention in hypertension, and more studies are needed to clarify this.
In primary prevention, the first study designed to investigate the use of aspirin in hypertension was the Hypertension Optimal Treatment (HOT) trial. 95 Hypertensive patients with optimal control of BP were randomized to receive either 75 mg daily of aspirin or placebo. Major CV events were reduced by 15% in the group receiving aspirin compared with placebo. Interestingly, the incidence of stroke in the aspirin group was not reduced, whereas, as expected, the incidence of bleeding events was higher in the aspirin group. This was the first study to show that, in hypertension, aspirin may confer an additional benefit in reducing the incidence of coronary heart disease beyond optimal control of BP.
However, due to the high incidence of minor and major bleeding events, the role of low-dose aspirin in primary prevention is not clear in hypertensives at low overall CV risk. The Thrombosis Prevention Trial was a double-blind, placebo-controlled trial in 5,499 men at risk for coronary heart disease. In the subgroup of the study with hypertension, no significant difference was observed in the rate of CV events. 96 A recent Cochrane review examined the role of aspirin therapy in primary prevention in hypertension. In a pooled analysis of the HOT study and the Thrombosis Prevention Trial, it was shown that there was no difference in CV events for aspirin as compared with placebo. It was concluded therefore that there is no benefit, as regards either all-cause mortality or CV events, in the use of aspirin in low-risk hypertensive patients for primary prevention. 97 A very recent meta-analysis, which included six primary prevention trials, among them the HOT and The Thrombosis Prevention Trial, similarly concluded that the use of aspirin in primary prevention remains uncertain, as the benefit in reduction of vascular events needs to be weighed against major gastrointestinal and extracranial bleeding events. 98 The recent guidelines from the European Society of Hypertension recommend the use of low dose aspirin for secondary prevention in all hypertensive patients with previous CV events, unless there is a contraindication. It is further suggested that, for primary prevention, low-dose aspirin be used only in patients with a total CV risk of >20% over 10 years, or in patients over the age of 50 years with moderate impairment of renal function. 99 A prerequisite for aspirin use in hypertensive patients is optimal control of BP before its use, in order to minimize the risk of developing a cerebral or other hemorrhagic event. Indeed, a retrospective analysis of the Thrombosis Prevention Trial showed that, among those hypertensives receiving 75 mg aspirin daily, the greatest reduction in risk for CV events occurred in those with optimal BP control. 100 In light of this evidence, there is a consensus that antiplatelet treatment is indicated in hypertensive patients at high risk of CV events. In the setting of primary prevention, more studies are needed in order to clarify, first, the importance of antiplatelet treatment in hypertensive patients; and second, the optimal type of antiplatelet therapy. As discussed above, clopidogrel may offer certain theoretical advantages over aspirin for primary prevention in hypertension. Additionally, being a potent inhibitor of MPA formation, not only will it exert antithrombotic effects, but may also prevent the progression of atherosclerosis in such patients. Indeed, the same may be true of other P2Y 12 receptor antagonists, although to date no data are available. Long-term prospective studies addressing this issue are needed.
conclusions
It is clear that there is an increased arterial thrombotic risk associated with essential hypertension. Enhanced platelet activation contributes importantly to this thrombotic state, and the use of antiplatelet therapy improves prognosis in hypertensive patients at high CV risk and in those with established clinically evident atherosclerotic disease. By contrast, the picture is not so clear in hypertensive patients who are at relatively low CV risk. The latest guidelines do not recommend the use of aspirin in all hypertensive patients. CV risk >20% over 10 years or age >50 years with moderate impairment of renal function are the two criteria principally used to justify the use of low-dose aspirin. Alternative antiplatelet treatments, in particular with clopidogrel, may prove in the future to confer not only antithrombotic but also antiatherosclerotic benefits in such patients. Long-term prospective comparative studies are needed to clarify these issues.
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